Stephanie Markovina1, Fenghai Duan2, Bradley S Snyder3, Barry A Siegel1, Mitchell Machtay4, Jeffrey D Bradley5. 1. Mallinckrodt Institute of Radiology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. 2. Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island. 3. Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island. 4. Department of Radiation Oncology, Case Western Reserve University, Cleveland, Ohio. 5. Mallinckrodt Institute of Radiology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. Electronic address: jbradley@radonc.wustl.edu.
Abstract
PURPOSE: The American College of Radiology Imaging Network (ACRIN) 6668/Radiation Therapy Oncology Group (RTOG) 0235 study demonstrated that standardized uptake values (SUV) on post-treatment [(18)F]fluorodeoxyglucose-positron emission tomography (FDG-PET) correlated with survival in locally advanced non-small cell lung cancer (NSCLC). This secondary analysis determined whether SUV of regional lymph nodes (RLNs) on post-treatment FDG-PET correlated with patient outcomes. METHODS AND MATERIALS: Included for analysis were patients treated with concurrent chemoradiation therapy, using radiation doses ≥60 Gy, with identifiable FDG-avid RLNs (distinct from primary tumor) on pretreatment FDG-PET, and post-treatment FDG-PET data. ACRIN core laboratory SUV measurements were used. Event time was calculated from the date of post-treatment FDG-PET. Local-regional failure was defined as failure within the treated RT volume and reported by the treating institution. Statistical analyses included Wilcoxon signed rank test, Kaplan-Meier curves (log rank test), and Cox proportional hazards regression modeling. RESULTS: Of 234 trial-eligible patients, 139 (59%) had uptake in both primary tumor and RLNs on pretreatment FDG-PET and had SUV data from post-treatment FDG-PET. Maximum SUV was greater for primary tumor than for RLNs before treatment (P<.001) but not different post-treatment (P=.320). Post-treatment SUV of RLNs was not associated with overall survival. However, elevated post-treatment SUV of RLNs, both the absolute value and the percentage of residual activity compared to the pretreatment SUV were associated with inferior local-regional control (P<.001). CONCLUSIONS: High residual metabolic activity in RLNs on post-treatment FDG-PET is associated with worse local-regional control. Based on these data, future trials evaluating a radiation therapy boost should consider inclusion of both primary tumor and FDG-avid RLNs in the boost volume to maximize local-regional control.
PURPOSE: The American College of Radiology Imaging Network (ACRIN) 6668/Radiation Therapy Oncology Group (RTOG) 0235 study demonstrated that standardized uptake values (SUV) on post-treatment [(18)F]fluorodeoxyglucose-positron emission tomography (FDG-PET) correlated with survival in locally advanced non-small cell lung cancer (NSCLC). This secondary analysis determined whether SUV of regional lymph nodes (RLNs) on post-treatment FDG-PET correlated with patient outcomes. METHODS AND MATERIALS: Included for analysis were patients treated with concurrent chemoradiation therapy, using radiation doses ≥60 Gy, with identifiable FDG-avid RLNs (distinct from primary tumor) on pretreatment FDG-PET, and post-treatment FDG-PET data. ACRIN core laboratory SUV measurements were used. Event time was calculated from the date of post-treatment FDG-PET. Local-regional failure was defined as failure within the treated RT volume and reported by the treating institution. Statistical analyses included Wilcoxon signed rank test, Kaplan-Meier curves (log rank test), and Cox proportional hazards regression modeling. RESULTS: Of 234 trial-eligible patients, 139 (59%) had uptake in both primary tumor and RLNs on pretreatment FDG-PET and had SUV data from post-treatment FDG-PET. Maximum SUV was greater for primary tumor than for RLNs before treatment (P<.001) but not different post-treatment (P=.320). Post-treatment SUV of RLNs was not associated with overall survival. However, elevated post-treatment SUV of RLNs, both the absolute value and the percentage of residual activity compared to the pretreatment SUV were associated with inferior local-regional control (P<.001). CONCLUSIONS: High residual metabolic activity in RLNs on post-treatment FDG-PET is associated with worse local-regional control. Based on these data, future trials evaluating a radiation therapy boost should consider inclusion of both primary tumor and FDG-avid RLNs in the boost volume to maximize local-regional control.
Authors: Bahman Emami; Nena Mirkovic; Charles Scott; Roger Byhardt; Mary V Graham; E James Andras; Madhu John; Arnold Herskovic; Raul Urtasun; Sucha O Asbell; Carlos A Perez; James Cox Journal: Lung Cancer Date: 2003-08 Impact factor: 5.705
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Angela van Baardwijk; Geert Bosmans; André Dekker; Marinus van Kroonenburgh; Liesbeth Boersma; Stofferinus Wanders; Michel Ollers; Ruud Houben; André Minken; Philippe Lambin; Dirk De Ruysscher Journal: Radiother Oncol Date: 2007-01-26 Impact factor: 6.280
Authors: Mitchell Machtay; Fenghai Duan; Barry A Siegel; Bradley S Snyder; Jeremy J Gorelick; Janet S Reddin; Reginald Munden; Douglas W Johnson; Larry H Wilf; Albert DeNittis; Nancy Sherwin; Kwan Ho Cho; Seok-Ki Kim; Gregory Videtic; Donald R Neumann; Ritsuko Komaki; Homer Macapinlac; Jeffrey D Bradley; Abass Alavi Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox Journal: Lancet Date: 2009-07-24 Impact factor: 79.321
Authors: C Schaake-Koning; L Schuster-Uitterhoeve; G Hart; D Gonzalez Gonzalez Journal: Int J Radiat Oncol Biol Phys Date: 1983-07 Impact factor: 7.038
Authors: Sinisa Stanic; Rebecca Paulus; Robert D Timmerman; Jeff M Michalski; Robert B Barriger; Andrea Bezjak; Gregory M M Videtic; Jeffrey Bradley Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-01 Impact factor: 7.038
Authors: Bruno Hochhegger; Matheus Zanon; Stephan Altmayer; Gabriel S Pacini; Fernanda Balbinot; Martina Z Francisco; Ruhana Dalla Costa; Guilherme Watte; Marcel Koenigkam Santos; Marcelo C Barros; Diana Penha; Klaus Irion; Edson Marchiori Journal: Lung Date: 2018-10-09 Impact factor: 2.584
Authors: Katja Pinker; Piotr Andrzejewski; Pascal Baltzer; Stephan H Polanec; Alina Sturdza; Dietmar Georg; Thomas H Helbich; Georgios Karanikas; Christoph Grimm; Stephan Polterauer; Richard Poetter; Wolfgang Wadsak; Markus Mitterhauser; Petra Georg Journal: PLoS One Date: 2016-05-11 Impact factor: 3.240
Authors: Sara Carvalho; Ralph T H Leijenaar; Esther G C Troost; Janna E van Timmeren; Cary Oberije; Wouter van Elmpt; Lioe-Fee de Geus-Oei; Johan Bussink; Philippe Lambin Journal: PLoS One Date: 2018-03-01 Impact factor: 3.240